Novel pharmacological targets for GABAergic dysfunction in ADHD
Neuropharmacology. 2024 Mar 8;249:109897. doi: 10.1016/j.neuropharm.2024.109897. Online ahead of print.ABSTRACTAttention deficit/hyperactivity disorder (ADHD) is a neurodevelopment disorder that affects approximately 5% of the population. The disorder is characterized by impulsivity, hyperactivity, and deficits in attention and cognition, although symptoms vary across patients due to the heterogenous and polygenic nature of the disorder. Stimulant medications are the standard of care treatment for ADHD patients, and their effectiveness has led to the dopaminergic hypothesis of ADHD in which deficits in dopaminergic signali...
Source: Neuropharmacology - March 10, 2024 Category: Drugs & Pharmacology Authors: Anthony S Ferranti Deborah J Luessen Colleen M Niswender Source Type: research
Novel pharmacological targets for GABAergic dysfunction in ADHD
Neuropharmacology. 2024 Mar 8:109897. doi: 10.1016/j.neuropharm.2024.109897. Online ahead of print.ABSTRACTAttention deficit/hyperactivity disorder (ADHD) is a neurodevelopment disorder that affects approximately 5% of the population. The disorder is characterized by impulsivity, hyperactivity, and deficits in attention and cognition, although symptoms vary across patients due to the heterogenous and polygenic nature of the disorder. Stimulant medications are the standard of care treatment for ADHD patients, and their effectiveness has led to the dopaminergic hypothesis of ADHD in which deficits in dopaminergic signaling, ...
Source: Neuropharmacology - March 10, 2024 Category: Drugs & Pharmacology Authors: Anthony S Ferranti Deborah J Luessen Colleen M Niswender Source Type: research
Novel pharmacological targets for GABAergic dysfunction in ADHD
Neuropharmacology. 2024 Mar 8:109897. doi: 10.1016/j.neuropharm.2024.109897. Online ahead of print.ABSTRACTAttention deficit/hyperactivity disorder (ADHD) is a neurodevelopment disorder that affects approximately 5% of the population. The disorder is characterized by impulsivity, hyperactivity, and deficits in attention and cognition, although symptoms vary across patients due to the heterogenous and polygenic nature of the disorder. Stimulant medications are the standard of care treatment for ADHD patients, and their effectiveness has led to the dopaminergic hypothesis of ADHD in which deficits in dopaminergic signaling, ...
Source: Neuropharmacology - March 10, 2024 Category: Drugs & Pharmacology Authors: Anthony S Ferranti Deborah J Luessen Colleen M Niswender Source Type: research
Retraction Notice to "Ibuprofen or piroxicam protects nigral neurons and delays the development of l-dopa induced dyskinesia in rats with experimental Parkinsonism: Influence on angiogenesis" [Neuropharmacology, 107 (2016) 432 - 450]
Neuropharmacology. 2024 May 1;248:109894. doi: 10.1016/j.neuropharm.2024.109894. Epub 2024 Mar 5.NO ABSTRACTPMID:38443226 | DOI:10.1016/j.neuropharm.2024.109894 (Source: Neuropharmacology)
Source: Neuropharmacology - March 5, 2024 Category: Drugs & Pharmacology Authors: Asmaa M Teema Sawsan A Zaitone Yasser M Moustafa Source Type: research
Retraction Notice to "Ibuprofen or piroxicam protects nigral neurons and delays the development of l-dopa induced dyskinesia in rats with experimental Parkinsonism: Influence on angiogenesis" [Neuropharmacology, 107 (2016) 432 - 450]
Neuropharmacology. 2024 Mar 4:109894. doi: 10.1016/j.neuropharm.2024.109894. Online ahead of print.NO ABSTRACTPMID:38443226 | DOI:10.1016/j.neuropharm.2024.109894 (Source: Neuropharmacology)
Source: Neuropharmacology - March 5, 2024 Category: Drugs & Pharmacology Authors: Asmaa M Teema Sawsan A Zaitone Yasser M Moustafa Source Type: research
Retraction Notice to "Ibuprofen or piroxicam protects nigral neurons and delays the development of l-dopa induced dyskinesia in rats with experimental Parkinsonism: Influence on angiogenesis" [Neuropharmacology, 107 (2016) 432 - 450]
Neuropharmacology. 2024 Mar 4:109894. doi: 10.1016/j.neuropharm.2024.109894. Online ahead of print.NO ABSTRACTPMID:38443226 | DOI:10.1016/j.neuropharm.2024.109894 (Source: Neuropharmacology)
Source: Neuropharmacology - March 5, 2024 Category: Drugs & Pharmacology Authors: Asmaa M Teema Sawsan A Zaitone Yasser M Moustafa Source Type: research
Retraction Notice to "Ibuprofen or piroxicam protects nigral neurons and delays the development of l-dopa induced dyskinesia in rats with experimental Parkinsonism: Influence on angiogenesis" [Neuropharmacology, 107 (2016) 432 - 450]
Neuropharmacology. 2024 Mar 4:109894. doi: 10.1016/j.neuropharm.2024.109894. Online ahead of print.NO ABSTRACTPMID:38443226 | DOI:10.1016/j.neuropharm.2024.109894 (Source: Neuropharmacology)
Source: Neuropharmacology - March 5, 2024 Category: Drugs & Pharmacology Authors: Asmaa M Teema Sawsan A Zaitone Yasser M Moustafa Source Type: research
Retraction Notice to "Ibuprofen or piroxicam protects nigral neurons and delays the development of l-dopa induced dyskinesia in rats with experimental Parkinsonism: Influence on angiogenesis" [Neuropharmacology, 107 (2016) 432 - 450]
Neuropharmacology. 2024 Mar 4:109894. doi: 10.1016/j.neuropharm.2024.109894. Online ahead of print.NO ABSTRACTPMID:38443226 | DOI:10.1016/j.neuropharm.2024.109894 (Source: Neuropharmacology)
Source: Neuropharmacology - March 5, 2024 Category: Drugs & Pharmacology Authors: Asmaa M Teema Sawsan A Zaitone Yasser M Moustafa Source Type: research
Quantitative T < sub > 2 < /sub > mapping-based longitudinal assessment of brain injury and therapeutic rescue in the rat following acute organophosphate intoxication
This study supports the utility of T2 mapping for longitudinally monitoring brain injury and highlights the therapeutic potential of ALLO as an adjunct therapy to mitigate chronic morbidity associated with acute OP intoxication.PMID:38437913 | DOI:10.1016/j.neuropharm.2024.109895 (Source: Neuropharmacology)
Source: Neuropharmacology - March 4, 2024 Category: Drugs & Pharmacology Authors: Alita Jesal D Almeida Brad A Hobson Naomi Saito Donald A Bruun Valerie A Porter Danielle J Harvey Joel R Garbow Abhijit J Chaudhari Pamela J Lein Source Type: research
Quantitative T < sub > 2 < /sub > mapping-based longitudinal assessment of brain injury and therapeutic rescue in the rat following acute organophosphate intoxication
This study supports the utility of T2 mapping for longitudinally monitoring brain injury and highlights the therapeutic potential of ALLO as an adjunct therapy to mitigate chronic morbidity associated with acute OP intoxication.PMID:38437913 | DOI:10.1016/j.neuropharm.2024.109895 (Source: Neuropharmacology)
Source: Neuropharmacology - March 4, 2024 Category: Drugs & Pharmacology Authors: Alita Jesal D Almeida Brad A Hobson Naomi Saito Donald A Bruun Valerie A Porter Danielle J Harvey Joel R Garbow Abhijit J Chaudhari Pamela J Lein Source Type: research
The MCs - Cytokines axis in ASD
Neuropharmacology. 2024 Feb 29:109890. doi: 10.1016/j.neuropharm.2024.109890. Online ahead of print.ABSTRACTAutism Spectrum Disorder (ASD) is a neurodevelopmental disturbance, diagnosed in early childhood. It is associated with varying degrees of dysfunctional communication and social skills, repetitive and stereotypic behaviors. Regardless of the constant increase in the number of diagnosed patients, there are still no established treatment schemes in global practice. Many children with ASD have allergic symptoms, often in the absence of mast cell (MC) positive tests. Activation of MCs may release molecules related to inf...
Source: Neuropharmacology - March 2, 2024 Category: Drugs & Pharmacology Authors: Eleonora Kovacheva Maria Gevezova Michael Maes Victoria Sarafian Source Type: research
Retigabine and gabapentin restore channel function and neuronal firing in a cellular model of an epilepsy-associated dominant-negative KCNQ5 variant
Neuropharmacology. 2024 Feb 28:109892. doi: 10.1016/j.neuropharm.2024.109892. Online ahead of print.ABSTRACTKCNQ5 encodes the voltage-gated potassium channel KV7.5, a member of the KV7 channel family, which conducts the M-current. This current is a potent regulator of neuronal excitability by regulating membrane potential in the subthreshold range of action potentials and mediating the medium and slow afterhyperpolarization. Recently, we have identified five loss-of-function variants in KCNQ5 in patients with genetic generalized epilepsy. Using the most severe dominant-negative variant (R359C), we set out to investigate ph...
Source: Neuropharmacology - March 1, 2024 Category: Drugs & Pharmacology Authors: Johanna Kr üger Holger Lerche Source Type: research
Exploring the therapeutic potential of cannabidiol for sleep deprivation-induced hyperalgesia
Neuropharmacology. 2024 Feb 28:109893. doi: 10.1016/j.neuropharm.2024.109893. Online ahead of print.ABSTRACTHyperalgesia resulting from sleep deprivation (SD) poses a significant a global public health challenge with limited treatment options. The nucleus accumbens (NAc) plays a crucial role in the modulation of pain and sleep, with its activity regulated by two distinct types of medium spiny neurons (MSNs) expressing dopamine 1 or dopamine 2 (D1-or D2) receptors (referred to as D1-MSNs and D2-MSNs, respectively). However, the specific involvement of the NAc in SD-induced hyperalgesia remains uncertain. Cannabidiol (CBD), ...
Source: Neuropharmacology - March 1, 2024 Category: Drugs & Pharmacology Authors: Kangsheng Zhu Siruan Chen Xia Qin Wanjun Bai Jie Hao Xiaolei Xu Han Guo Hui Bai Zuxiao Yang Sheng Wang Zongmao Zhao Tengfei Ji Dezhi Kong Wei Zhang Source Type: research
Retigabine and gabapentin restore channel function and neuronal firing in a cellular model of an epilepsy-associated dominant-negative KCNQ5 variant
Neuropharmacology. 2024 Feb 28:109892. doi: 10.1016/j.neuropharm.2024.109892. Online ahead of print.ABSTRACTKCNQ5 encodes the voltage-gated potassium channel KV7.5, a member of the KV7 channel family, which conducts the M-current. This current is a potent regulator of neuronal excitability by regulating membrane potential in the subthreshold range of action potentials and mediating the medium and slow afterhyperpolarization. Recently, we have identified five loss-of-function variants in KCNQ5 in patients with genetic generalized epilepsy. Using the most severe dominant-negative variant (R359C), we set out to investigate ph...
Source: Neuropharmacology - March 1, 2024 Category: Drugs & Pharmacology Authors: Johanna Kr üger Holger Lerche Source Type: research
Exploring the therapeutic potential of cannabidiol for sleep deprivation-induced hyperalgesia
Neuropharmacology. 2024 Feb 28:109893. doi: 10.1016/j.neuropharm.2024.109893. Online ahead of print.ABSTRACTHyperalgesia resulting from sleep deprivation (SD) poses a significant a global public health challenge with limited treatment options. The nucleus accumbens (NAc) plays a crucial role in the modulation of pain and sleep, with its activity regulated by two distinct types of medium spiny neurons (MSNs) expressing dopamine 1 or dopamine 2 (D1-or D2) receptors (referred to as D1-MSNs and D2-MSNs, respectively). However, the specific involvement of the NAc in SD-induced hyperalgesia remains uncertain. Cannabidiol (CBD), ...
Source: Neuropharmacology - March 1, 2024 Category: Drugs & Pharmacology Authors: Kangsheng Zhu Siruan Chen Xia Qin Wanjun Bai Jie Hao Xiaolei Xu Han Guo Hui Bai Zuxiao Yang Sheng Wang Zongmao Zhao Tengfei Ji Dezhi Kong Wei Zhang Source Type: research
